Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine plus desloratadine for G-CSF-associated pain in patients with cancer receiving chemotherapy
IRCT20210415050976N19Phase 2Completed
- Sponsor
- Jahrom University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial comparing Famotidine plus desloratadine with Placebo (2 arms). Primary endpoint: Pain. Started May 2026; status: completed.
02
Drugs
famotidinedesloratadine
Beyond the preview
Go deeper on IRCT20210415050976N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210415050976N19.